- Home
- EXEL vs VERA Comparison
EXEL vs VERA Comparison
Compare EXEL & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- VERA
- Stock Information
- Founded
- EXEL 1994
- VERA 2016
- Country
- EXEL United States
- VERA United States
- Employees
- EXEL N/A
- VERA N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- EXEL Health Care
- VERA Health Care
- Exchange
- EXEL Nasdaq
- VERA Nasdaq
- Market Cap
- EXEL 12.0B
- VERA 2.0B
- IPO Year
- EXEL 2000
- VERA 2021
- Fundamental
- Price
- EXEL $45.55
- VERA $23.60
- Analyst Decision
- EXEL Buy
- VERA Buy
- Analyst Count
- EXEL 18
- VERA 8
- Target Price
- EXEL $43.65
- VERA $64.63
- AVG Volume (30 Days)
- EXEL 3.7M
- VERA 1.4M
- Earning Date
- EXEL 08-05-2025
- VERA 08-07-2025
- Dividend Yield
- EXEL N/A
- VERA N/A
- EPS Growth
- EXEL 237.58
- VERA N/A
- EPS
- EXEL 2.20
- VERA N/A
- Revenue
- EXEL $2,298,922,000.00
- VERA N/A
- Revenue This Year
- EXEL $9.37
- VERA N/A
- Revenue Next Year
- EXEL $11.05
- VERA N/A
- P/E Ratio
- EXEL $20.36
- VERA N/A
- Revenue Growth
- EXEL 24.49
- VERA N/A
- 52 Week Low
- EXEL $22.13
- VERA $18.53
- 52 Week High
- EXEL $49.62
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- EXEL 56.79
- VERA 52.93
- Support Level
- EXEL $43.21
- VERA $22.57
- Resistance Level
- EXEL $48.74
- VERA $24.58
- Average True Range (ATR)
- EXEL 2.01
- VERA 1.22
- MACD
- EXEL 0.05
- VERA 0.14
- Stochastic Oscillator
- EXEL 31.61
- VERA 69.80
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.